AR and neoplasm: Bicalutamide may also function as an androgen receptor agonist when androgen receptors are overexpressed (which may occur in up to 30 % of CRPC tumours) [27–29], with certain mutations of the androgen receptor [30] or in the setting of inflammation [31, 32].